New findings indicate that Juvenile Huntington's should be separated into two distinct categories, which in turn may be treated differently. [...]
From 13thto 16thof September, to important meetings took place in Vienna: the EHA Business Meeting and the EHDN Plenary Meeting. [...]
The European Medicines Agency has acknowledged the huntingtin lowering drug, RG6042 (previously known as IONIS-HTTRx), as a possible therapy that […]
Read about the Registery journey from the very beginning to the more recent successor study Enroll-HD. Cristina Ferreira gives you […]
Roche Pharmaceuticals is currently working on their Huntingtin Lowering drug, RG6042 (formerly known as IONIS-HTTRx). In the letter Patient Partnership […]
Yesterday Ionis Pharmaceutical presented new data from their Huntingtin lowering trial, IONIS-HTTRx. The data demonstrates a relationship between reduction of […]
The first weekend in February was historical: it was the first meeting of the Huntington’s Disease Coalition for Patient Engagement […]
The biotechnology company Wave Life Sciences strengthens their efforts in Huntington’s disease. In February they announced their collaboration with Takeda, […]
News and updates from the latest CHDI Therapeutics conferences have now been subtitled! In the video you can learn more [...]
Read about the Fellowship Programme, get an update on clinical trials, get to know Ed Wild better and get dates […]
Funding Partners
Follow us